Kornimate/medical-research-clean huggingface dataset:
the less is more study

Conditions: Alcohol Use

Summary: in this project, the investigators will implement innovations to extend use of contingency management (cm) to facilitate alcohol use reduction among people living with hiv (plwh). the investigators' approach to extending cm will use mobile health (mhealth) tools including a smartphone breathalyzer device with accompanying app and a wrist worn alcohol biosensor. participants will be engaged in mobile facilitated cm for 30-60 days with follow-up out to 6 months.


Eligibility criteria:
inclusion criteria: * frequent alcohol use in the past 30 days based on responses on the timeline followback (tlfb; sobell and sobell, 2003) * hiv positive * fluency in english * willingness to attempt alcohol abstinence for at least 30 days and then to attempt alcohol use on fewer days than at baseline after that * willingness to use smartphone applications and biosensor devices (i.e., breathalyzer device and wrist sensor) for alcohol use reduction purposes in the study. if participants do not have a compatible smartphone to use, they will be loaned one by the study exclusion criteria: * psychiatric conditions that would interfere with participation in the study * current alcohol withdrawal as indicated by a score of 8 or higher on the clinical institute withdrawal scale (ciwa; sullivan et al., 1989) or lifetime history of medically assisted detoxification * two positive breath alcohol concentration (brac) readings (i.e., \> 0.00%) at an in-person screening appointment. after participants blow their first positive brac, they will be allowed to reschedule and participate at another time, however if they blow a second positive brac, they will be excluded from this study and offered referrals for alcohol treatment. * currently seeking or past-12-month history of inpatient or intensive treatment for addictive behaviors * psychosis or other severe psychiatric disability * pregnancy, nursing or lack of reliable birth control use for women who have not yet reached menopause
comparison of two bronchodilator inhalers in pediatric asthmatics

Conditions: Asthma

Summary: this study is designed to evaluate the single-dose effectiveness of two bronchodilator inhalers given at two dose levels in pediatric asthma patients.


Eligibility criteria:
inclusion criteria: * persistent asthma for a minimum of six months duration that has been stable for at least four weeks * predicted fev1 60-90% * demonstration of 12% airway reversibility exclusion criteria: * continuous requirement for beta-blockers, monoamine oxidase (mao) inhibitors, tricyclic antidepressants, anticholinergics and/or steroids other than those inhaled; * presence of clinically-significant non-asthmatic acute or chronic disease
dopaminergic function and food reward

Conditions: Adiposity; Weight Loss

Summary: the broad aim of the study is to obtain a better understanding of alterations in mesolimbic reward pathways in adiposity based on the hypothesis of a hypofunctioning reward system in obesity. this will be achieved by integrating a functional neuroimaging (fmri) with behavioral reward tasks and the modulation of the dopamine level by dopamine depletion.


Eligibility criteria:
inclusion criteria: * female * healthy exclusion criteria: * fmri contraindications * claustrophobia
comparison of two techniques of combination therapy for treatment of obstructive sleep apnea (osa)

Conditions: Treatment for Obstructive Sleep Apnea

Summary: to study the effects of two combination therapies for patients with obstructive sleep apnea (osa) who have been both intolerant to positive airway pressure (pap) therapy and sub-therapeutic to oral appliance therapy. hypothesis 1. there is a difference between continuous positive airway pressure (cpap) vs cpap/oral appliance (oa) connect vs cpap/oa disconnected in terms of: 1. apnea hypopnea index (ahi) reduction 2. amount of side effects 3. amount of leaks 4. hours of use (compliance) 5. cpap pressure 2. there is a difference between connected and disconnected for the following symptoms: 1. epworth sleepiness scale (ess) 2. functional outcomes of sleep questionnaire (fosq) 3. side effects study design - randomized prospective parallel


Eligibility criteria:
inclusion criteria: baseline diagnosis ahi \> or = 5 plus ess . or = 10. * pap intolerance * partial response to oral appliance therapy: ahi \> 5 * age: \> 18 exclusion criteria: history of daily use of alcohol, narcotics or central nervous system (cns) depressants. * diagnosis of central sleep apnea * pregnancy * edentulous * prisoners
behavioral neurocardiac training and hypertension

Conditions: Hypertension

Summary: this randomized controlled trial will examine whether behavioral neurocardiac training with heart rate variability biofeedback (bnt) augments reduction in ambulatory daytime and 24-hour sbp, dbp and pp, in comparison to an active control intervention (ac, autogenic relaxation training), among subjects diagnosed with hypertension, and following adjustment for medications. in addition, the independent association between the bnt and ac interventions on vagal-heart rate modulation and baroreflex sensitivity will be evaluated during a standardized assessment protocol of mental stress testing. this study extends a previous trial conducted at the uhn, in which we reported that the biofeedback intervention independently augments vagal-heart rate modulation, while reducing symptoms of stress and depressed mood, among subjects diagnosed with cardiovascular disease. exploratory features of this trial will examine the association between ambulatory blood pressure, vagal-heart rate modulation, baroreflex sensitivity, and markers of inflammatory activity.


Eligibility criteria:
inclusion criteria: * 35 to 64 years of age * diagnosis of grade 1 or 2 hypertension (140-159 mmhg or 160-180 mmhg sbp; or 90-99 or 100-110 mmhg dbp, respectively). * among subjects not prescribed medication, hypertension confirmed by ambulatory bp monitoring: mean 24-hour sbp \> 130 mmhg or dbp \> 80 mmhg. * subjects prescribed antihypertensive pharmacotherapy are required to have a treatment regimen that was unchanged for at least 4 months prior to enrollment. exclusion criteria: * diagnosis of cardiovascular disease, clinically significant arrhythmia, sleep disorder, psychiatric illness (eg. psychosis), alcohol/drug dependence within the previous year, or an inability to comprehend english or french

Keywords: hypertension biofeedback relaxation training
covid-19 and pregnancy: placental and immunological impacts

Conditions: Covid19

Summary: the aim of this study is to compare placental pathologies in patients with covid 19 infection at the time of childbirth or a history of covid 19 during pregnancy versus control patients

the second wave of covid 19 is currently sweeping through europe. if the first wave brought reassuring elements on the risk of maternal-fetal transmission, it nevertheless counted an increase in severe maternal forms in the third trimester associated with more premature deliveries and cesarean sections. in addition, due to the very recent nature of this new infection, we have little data on the effect of sars-cov 2 contracted during pregnancy on the fetus and on maternal-fetal exchanges. publications report an increase in growth retardation, maternal coagulopathies, preeclampsia and placental thrombosis. the vascular placental abnormalities observed in the first series must be confirmed and refined. finally, pregnancy is marked by immunomodulation which can interfere with immune reactions. a better understanding of the immunological mechanisms in the mother and of the immunity transmitted to the fetus is necessary to better understand the maternal-fetal issues of covid 19. this prospective study concerns patients presenting for their delivery at foch hospital. 4 groups of patients will be identified in the delivery room after childbirth based on their covid 19 pcr taken within 72 hours, their covid 19 serology, or a history of positive covid 19 pcr during pregnancy : 1 control group of 50 patients, 1 group of 50 asymptomatic patients, 1 group of 50 patients with symptoms, and 1 group of 50 cured patients who contracted the disease during pregnancy. the patients will have various samples: blood, umbilical cord blood, umbilical cord, placenta

Eligibility criteria:
inclusion criteria: * patient pregnant for more than 20 weeks with amenorrhea * having completed a covid 19 pcr within 72 hours * admitted to the birthing room at foch hospital for her delivery exclusion criteria: * minor (age \<18 years, on inclusion) * diabetes with and without insulin (only for the control group) * high blood pressure (only for the control group), * preeclampsia (only for the control group) * infection during pregnancy: hiv, toxoplasmosis, rubella, cmv, syphilis. * pcr influenza a or b positive, proven by nasopharyngeal swab in the week preceding childbirth
sleep as a model to understand and manipulate cortical activity in order to promote functional recovery after stroke

Conditions: Hemispatial Neglect

Summary: brain functions are supported by multiple cell types, including neuronal and non-neuronal cells that are connected into complex networks. when the connectivity between those cells is altered or disrupted, the functioning of the brain is impaired. in stroke, the interruption of blood supply to the neural circuits results in connectivity damage and permanent disabilities. experimental evidence suggests that some types of brain state, including sleep, can protect brain tissue from stroke and "repair" the damaged circuits. this project will investigate the neuronal mechanism underlying the protective effect of sleep on brain connectivity and network activity. to this end, the investigators will use a collection of state-of-the-art technologies including high-density electroencephalography (hd-eeg), transcranial magnetic stimulation (tms) and transcranial alternating current stimulation (tacs). perspectives include a better understanding of the causes and consequences of the perturbed electrical activity of the brain during sleep in stroke patients.


Eligibility criteria:
inclusion criteria: * informed consent as documented by signature * age between 18 and 80 years * first-ever right-sided stroke * normal or corrected to normal vision * demonstration of left hemispatial neglect (after a right-hemispheric brain lesion) found in a comprehensive neuropsychological test battery and clinical assessment * at least 3 weeks post-stroke exclusion criteria: * concomitant neurodegenerative diseases * psychiatric diseases * decompressive craniectomy * history of documented sleep disorders in the medical record (e.g. insomnia, hypersomnia, rem-sleep behaviour disorder) * epileptic seizures * implanted medical devices (e.g.: pacemakers, cochlear implants, implanted neurostimulators) * presence of metal in the region of the head (excluding fixed dental implants such as tooth fillings or fixed dental braces) * medication with drugs possibly lowering the seizure threshold * alcohol or drug abuse * inability to follow the procedures of the study * for female patients: in order to participate in the study, female patients in reproductive age need to take a pregnancy test (a standard urine pregnancy test will be provided).
evaluation of different rapid orthodontic expansion devices

Conditions: Cross Bite

Summary: evaluating and comparing the short term effects of different palatal expanders on the amount of palatal expansion and buccal tipping of posterior teeth. hypothesis: h0: there is no difference in the short term effects between the different palatal expanders. h1: there is a significant difference in the short term effects between the different palatal expanders.


Eligibility criteria:
inclusion criteria: * non-syndromic adolescent patients. * patients in need for palatal expansion treatment. * average face height. * no previous orthodontic treatment. exclusion criteria: * syndromic adolescent patients. * patients not in need for palatal expansion treatment. * non-average face height. * previous orthodontic treatment.
trend-hd - a trial of ethyl-epa (miraxion™) in treating mild to moderate huntington's disease

Conditions: Huntington Disease

Summary: this study is designed to determine the effect of 2 gram/day of ethyl-epa on motor (movement) signs and symptoms of huntington disease.

multi-center, double blind, placebo-controlled study with parallel groups of outpatients with early, symptomatic huntington's disease. participants will be randomized to receive 1 gram twice daily (2 gram/day total daily dose) of active study drug or placebo. the 6-month placebo-controlled phased will be followed by a subsequent 6-month open-label extension phase with all subjects receiving 1 gram twice daily (2 grams/day total daily dose) of active study drug.

Eligibility criteria:
inclusion criteria: * clinical features of huntington's disease (hd) and confirmatory family history of hd, and/or cag repeat expansion greater than or equal to 36 * ambulatory, not requiring skilled nursing care (total functional capacity \[tfc\] greater than or equal to 7) * chorea score of at least 2 in one extremity (uhdrs) * maximal dystonia less than or equal to 2 and maximal bradykinesia less than or equal to 2 * 35 years of age or older of either gender * must be on stable dosages of non-competitive nmda receptor antagonists, and/or antiepileptic medications for 60 days prior to baseline * females of child-bearing potential must use adequate birth control exclusion criteria: * history of established diagnosis of tardive dyskinesia * clinical evidence of unstable medical or psychiatric illness * clinically significant active and unstable psychotic disease (hallucinations or delusions) * major depression (beck depression inventory \[bdi\]-ii score greater than 20) at screening visit * suicidal ideation (bdi-ii item 9 greater than or equal to 2) at screening visit * history of clinically significant substance abuse within 12 months of baseline visit * pregnant/lactating women * participation in other drug studies within 60 days prior to baseline visit * previous participation in any investigational study of ethyl-epa (miraxion™) * use of aspirin at daily dosage greater than 325 mg/day * exclusionary drugs (within 6 months baseline visit): depot neuroleptics * exclusionary drugs (within 60 days baseline visit): omega-3 supplementation, tetrabenazine or reserpine, high dose and/or variable dose oral anti-psychotic medications, steroid (other than topical), selenium supplements greater than 55 mcg/day, lithium, benzodiazepines (except for low dose), anticoagulants

Keywords: trial ethyl-epa miraxion™ treating mild moderate huntington's
named patient program for mitomycin for pyelocalyceal solution

Conditions: Urothelial Cancer of Renal Pelvis; Urothelial Carcinoma of the Renal Pelvis and Ureter; Urothelial Carcinoma Ureter; Urothelial Carcinoma Ureter Recurrent; Urothelial Carcinoma; Urothelial Carcinoma Recurrent

Summary: this program provides controlled, pre-approval access to jelmyto in response to unsolicited requests by physicians, hospitals, pharmacies, distributors, ministries of health or other parties on behalf of specific, or named patients, in select countries where jelmyto has not yet received a marketing authorization and in situations when patients have exhausted all available treatment options.


Eligibility criteria:
inclusion criteria: * patients who are suitable to receive jelmyto and for whom there is reasonable expectation that jelmyto may provide clinical benefit based on the medical judgment of their prescribing physician.

Keywords: low-grade upper tract urothelial cancer lg-utuc ugn-101 mitomycin
artificial intelligence-based motion analysis for early detection of copd

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Summary: this study aims to develop a non-invasive and contact-free diagnostic system that uses artificial intelligence (ai) to detect chronic obstructive pulmonary disease (copd) by analyzing walking patterns. participants in this study will include individuals with a diagnosis of copd and healthy volunteers. all participants will undergo a 6-minute walk test (6mwt), during which their movements will be recorded using video. in addition, they will complete a breathing test (spirometry) and a short questionnaire about symptoms. the recorded videos will be analyzed using an ai model based on motion tracking software. this model will evaluate walking-related parameters such as step count, step length, walking time, and total walking distance. the goal is to determine whether walking patterns can be used to detect copd with high accuracy, especially in situations where traditional lung function tests may not be available or feasible. this study is observational and does not involve any experimental drug or treatment. the results may help to create new diagnostic tools that are easy to use, safe, and accessible for early detection of copd.


Eligibility criteria:
inclusion criteria: * aged between 40 and 80 years * ability to provide informed consent * for copd group: previously diagnosed with copd based on gold criteria (fev1/fvc \< 0.70) * for control group: no history of pulmonary disease and normal spirometry results * physically able to perform the 6-minute walk test * willingness to participate in video recording during gait analysis exclusion criteria: * younger than 40 or older than 80 years * acute respiratory tract infection or other active infections * severe heart failure, advanced arrhythmias, or other serious cardiovascular conditions * physical disability preventing completion of the 6-minute walk test * neurological or orthopedic conditions causing major gait disturbance * inability to perform spirometry due to physical or cognitive limitations * pregnant or breastfeeding women diagnosed with other serious pulmonary diseases (e.g., interstitial lung disease, active tuberculosis) refusal to give informed consent or to be video recorded

Keywords: chronic obstructive pulmonary disease artificial intelligence motion analysis 6-minute walk test spirometry
a trial for the safety and effectiveness of a novel antimicrobial-coated foley catheter for reduction of cauti.

Conditions: Urinary Tract Infection

Summary: the primary objective of this pilot study is to demonstrate the feasibility of recruiting eligible patients for the purposes of assessing the temporal aspects and rates of catheter associated urinary tract infection (cauti), based on the agreed-upon case definition so that the numbers needed for a pivotal study can be better estimated.

this pilot study will be a prospective, single site, randomized clinical investigation comparing the safety and effectiveness of the icet tic antimicrobial foley catheter, against the infection control standard-of-care, the bard ® lubri-sil® i.c. foley catheter. approximately 160 patients will be screened. the study has been designed to enroll approximately 120 eligible subjects to obtain about 60 evaluable subjects (30 in each arm). subjects who meet the eligibility criteria will be enrolled into the study and randomly assigned to the experimental or standard-of-care group in a 1:1 ratio.

Eligibility criteria:
inclusion criteria: 1. subject is at least 18 years of age 2. subject is expected to be catheterized with 14 or 16 french foley catheters for at least 72 hours. 3. subject (or a legally authorized representative) has provided written informed consent for study participation and procedures to be performed. 4. life expectancy at least 3 months or more in the judgment of the investigator exclusion criteria: 1. subjects who present with previously known, symptomatic uti 2. subjects with a positive urine dipstick at the time of enrollment 3. subjects who are on systemic antibiotics within 48 hours prior to enrollment 4. subjects with a known of suspected allergy to silicone, silver or silver compounds causing delayed hypersensitivity reactions or contact dermatitis. 5. subjects who have had an indwelling catheter removed less than 48 hours before study enrollment. 6. current genitourinary tract surgery or known infection 7. subject requires use of a non-study urinary catheter 8. subjects known to be pregnant or breast feeding at the time of enrollment

Keywords: catheter associated urinary tract infections cauti
psychological impact of quarantine in chronic pain patient during covid-19 outbreak

Conditions: Sars-CoV2; Chronic Pain

Summary: in the context of quarantine with covid-19, we will study the experience and psychological impact of pain in adult patients living with chronic pain. we will evaluate the link between the question of physical and psychological confinement in the experience of pain in this particular situation


Eligibility criteria:
inclusion criteria: * patient with chronic pain * patient in confinement * patient with sufficient understanding of the french language exclusion criteria: * non adult patient * patient without quarantine

Keywords: psychological impact covid-19
patterns of coronary artery anatomy in children with congenital heart disease by computed tomography

Conditions: Heart Diseases

Summary: to test the ability of electron beam ct in evalting the coronary artery pattern in children with congenital heart disease.

to test the ability of electron beam ct in evalting the coronary artery pattern in children with congenital heart disease.

Eligibility criteria:
inclusion criteria: - tof, dorv, tga, cct exclusion criteria: -

Keywords: coronary artery